HALO: Summary for Halozyme Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 7:09am EST - Canadian Markets open in 2 hours and 21 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Halozyme Therapeutics, Inc. (HALO)

On Feb 9: 5.49 USD 0.00 (0.00%)

MORE ON HALO

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Halozyme Therapeutics, Inc. (NGM:HALO) Delayed quote data

Last Trade:	5.49 USD
Trade Time:	Feb 9
Change:	0.00 (0.00%)
Prev Close:	5.49
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	10.75

Day's Range:	N/A - N/A
52wk Range:	3.93 - 8.09
Volume:	0
Avg Vol (3m):	391,400
Market Cap:	503.14M
P/E (ttm):	N/A
EPS (ttm):	-0.74
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add HALO to Portfolio

Download Data

HEADLINES

•	HALOZYME THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers
	EDGAR Online (Tue 8:30am)

•	[video] Trading Smallcap Biotech
	at TheStreet.com (Mon, Feb 1)

•	Halozyme signs research contract with BioAtla
	AP (Tue, Jan 19)

•	Halozyme Announces Research Alliance with BioAtla for Conditionally Active Biologics
	Business Wire (Tue, Jan 19)

•	HALOZYME THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure
	EDGAR Online (Mon, Jan 11)

•	Halozyme to Present at J.P. Morgan Healthcare Conference on January 13
	Business Wire (Wed, Jan 6)

•	Halozyme, Beazer: Early Volume Plays
	at TheStreet.com (Wed, Jan 6)

•	HALOZYME THERAPEUTICS INC Financials
	EDGAR Online Financials (Wed, Nov 11)

•	Halozyme Earnings Call scheduled for 11:00 am ET today
	CCBN (Fri, Nov 6)

•	HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
	EDGAR Online (Fri, Nov 6)

More Headlines for HALO...

ANALYST

EPS Est (next year) (Dec-09) :	-0.70
EPS Est (in 2 years) (Dec-10) :	-0.66
Avg Rec (current)*:	1.8
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Halozyme Therapeutics, Inc., a biopharmaceutical company, develops and commercializes products targeting the extracellular matrix for the endocrinology, oncology, dermatology, and drug delivery markets.

Full Company Profile

Add to Portfolio

Email to a Friend

•